1 SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report June 29, 2001 BARR LABORATORIES, INC. (Exact name of registrant as specified in its charter) New York 1-9860 22-1927534 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519 (Address of principal executive offices) (Zip code) (845) 362-1100 (Registrant's telephone number, including area code) 1 2 BARR LABORATORIES, INC. CURRENT REPORT dated June 29, 2001 Item 5. Other Events See attached Exhibit 99.5, press release announcing that the Company and Duramed Pharmaceuticals, Inc. Boards of Directors have unanimously approved, and both companies have signed, a definitive agreement for a stock-for-stock merger of the two companies. Item 7. Financial Statements and Exhibits (c) Exhibit Number Exhibit -------------- ------- 99.5 Registrant's June 29, 2001 press release announcing that the Company and Duramed Pharmaceuticals, Inc. Boards of Directors have unanimously approved, and both companies have signed, a definitive agreement for a stock-for-stock merger of the two companies. 2 3 BARR LABORATORIES, INC. CURRENT REPORT dated June 29, 2001 SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BARR LABORATORIES, INC. Date: June 29, 2001 /S/ William T. McKee William T. McKee Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 3